ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,433.74
      0.00%
      US Tech 100
      19,042.00
      -0.14%
      Dow Jones
      38,647.10
      0.00%
      Brent Oil
      83.065
      1.33%
      Bitcoin
      67,231.51
      0.71%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Innate Pharma SA (IPHA)

      7. Innate Pharma SA (IPHA) News

      IPHA

      Innate Pharma (IPHA)

      Innate Pharma SA
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IPHA
      DateTimeSourceHeadlineSymbolCompany
      6:07AMiHub NewswireFeaturedFifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates
      06/04/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      06/04/20241:00AMBusiness WireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesNASDAQ:IPHAInnate Pharma SA
      06/04/20241:00AMBusiness WireInnate Pharma présente les résultats positifs de l’étude de Phase 2 TELLOMAK évaluant lacutamab dans le mycosis fongoïdeNASDAQ:IPHAInnate Pharma SA
      05/28/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      05/28/20241:00AMBusiness WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
      05/28/20241:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
      05/24/20246:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      05/24/20241:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingNASDAQ:IPHAInnate Pharma SA
      05/24/20241:00AMBusiness WireInnate Pharma partage les abstracts sélectionnés pour le congres annuel de l’ASCO 2024NASDAQ:IPHAInnate Pharma SA
      05/23/20244:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      05/23/20244:00PMBusiness WireOutcome of Innate Pharma’s 2024 Annual General MeetingNASDAQ:IPHAInnate Pharma SA
      05/23/20244:00PMBusiness WireRésultats de l’Assemblée Générale mixte du 23 mai 2024NASDAQ:IPHAInnate Pharma SA
      05/21/20241:00AMBusiness WireInnate Pharma: Clarification Regarding SAR443579 DesignationNASDAQ:IPHAInnate Pharma SA
      05/21/20241:00AMBusiness WireInnate Pharma: Clarification concernant le statut de SAR443579NASDAQ:IPHAInnate Pharma SA
      05/15/20246:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      05/15/20241:00AMBusiness WireInnate Pharma partage les abstracts sélectionnés pour le congrès 2024 de l’EHANASDAQ:IPHAInnate Pharma SA
      05/15/20241:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressNASDAQ:IPHAInnate Pharma SA
      05/14/20241:00AMBusiness WireInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
      05/14/20241:00AMBusiness WireInnate Pharma fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
      05/07/20241:00AMBusiness WireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateNASDAQ:IPHAInnate Pharma SA
      05/07/20241:00AMBusiness WireInnate Pharma organise une conférence téléphonique pour présenter ses résultats au premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024NASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsNASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireL’Assemblée Générale d’Innate Pharma aura lieu le 23 mai 2024NASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireInnate Pharma annonce la progression de l’essai clinique évaluant le NK Cell Engager SAR443579 / IPH6101 développé par Sanofi vers la Phase 2 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
      04/10/20241:00AMBusiness WireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateNASDAQ:IPHAInnate Pharma SA
      04/10/20241:00AMBusiness WireInnate Pharma présente des données d’efficacité précliniques pour IPH45, son conjugué anticorps-médicament innovant ciblant nectine-4 a l’AACR 2024NASDAQ:IPHAInnate Pharma SA
      04/09/20241:00AMBusiness WireInnate Pharma annonce sa participation à une prochaine Conférence InvestisseursNASDAQ:IPHAInnate Pharma SA
      04/09/20241:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
       Showing the most relevant articles for your search:NASDAQ:IPHA